Durvalumab regimen extends PFS in certain patients with liver cancer
Click Here to Manage Email Alerts
Durvalumab combined with transarterial chemoembolization and bevacizumab lengthened PFS among certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.
Topline data results from the randomized phase 3 EMERALD-1 trial showed no new safety issues associated with use of durvalumab (Imfinzi, AstraZeneca) — a PD-L1 inhibitor— when given in combination with transarterial chemoembolization (TACE) and bevacizumab (Avastin, Genentech).
“Patients with liver cancer eligible for embolization experience high rates of progression or recurrence and do not have the opportunity for early intervention with effective systemic therapy,” Riccardo Lencioni, MD, professor and director of the cancer imaging program in the department of diagnostic and interventional radiology at Pisa University Hospital in Italy, said in an AstraZeneca press release. “These results for durvalumab plus bevacizumab have the potential to reshape the treatment of this complex disease with a poor prognosis by showing for the first time that adding an immunotherapy combination to TACE significantly improves progression-free survival.”
The double-blind phase 3 EMERALD-1 trial assessed the efficacy of durvalumab with or without bevacizumab until disease progression vs. TACE alone among 616 patients with hepatocellular carcinoma eligible for embolization.
PFS served as the primary endpoint for durvalumab and TACE plus bevacizumab vs. TACE alone, with secondary endpoints of PFS for durvalumab plus TACE, OS, patient-reported outcomes and objective response rate.
Safety results in the trial appeared consistent with prior studies evaluating both agents and TACE.
Complete results will be presented at an upcoming medical meeting and shared with relevant regulatory authorities, according to the manufacturer.
Read more about
Click Here to Manage Email Alerts